Database : MEDLINE
Search on : neoplasms [Words]
References found : 2170453 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 217046 go to page                         

  1 / 2170453 MEDLINE  
              next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 26937907
[Au] Autor:Chang HT; Chen CK; Lin MH; Chou P; Chen TJ; Hwang SJ
[Ad] Address:From the Department of Family Medicine, Taipei Veterans General Hospital, and School of Medicine and Institute of Public Health and Community Medicine Research Center, National Yang-Ming University (H-TC); Department of Radiology, Taipei Veterans General Hospital, and School of Medicine and Institute of Clinical Medicine, National Yang-Ming University (C-KC); Department of Family Medicine, Taipei Veterans General Hospital, and School of Medicine, National Yang-Ming University (M-HL and S-JH); Institute of Public Health and Community Medicine Research Center, National Yang-Ming University (PC); and Department of Family Medicine, Taipei Veterans General Hospital, and School of Medicine and Institute of Hospital and Health Care Administration, National Yang-Ming University (T-JC), Taipei, Taiwan.
[Ti] Title:Readmissions in Cancer Patients After Receiving Inpatient Palliative Care in Taiwan: A 9-Year Nationwide Population-Based Cohort Study.
[So] Source:Medicine (Baltimore);95(8):e2782, 2016 Feb.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Few studies have reported on readmissions among cancer patients receiving inpatient palliative care (IPC). This study investigated readmissions in cancer patients after their first discharge from IPC in Taiwan from 2002 to 2010.This study was a secondary data analysis using information from the National Health Insurance Database in Taiwan from 2002 to 2010. We included subjects ≥20 years old diagnosed with malignant neoplasms who were listed in the registry of catastrophic illness. Patients diagnosed with cancer before January 1, 2002 or who had ever been admitted to an inpatient hospice palliative care unit before the study period were excluded. Readmission was defined as hospital readmission at least once after discharge from first admission to IPC until mortality or the end of the study period.A total of 42,022 patients who met the inclusion criteria were identified. The majority of these patients were male (60.4%). The mean age of cancer diagnosis was 64.0 ±â€Š14.4 years for men and 64.5 ±â€Š14.7 years for women. The mean age at first hospice ward admission was 65.2 ±â€Š14.2 years for men and 65.9 ±â€Š14.9 years for women. During their first admission to IPC, 59.2% patients died, and the median stay of first IPC admission was 8.0 days. Among those discharged alive from their first admission to IPC, 64.9% were readmitted, and 19.4% of these patients were readmitted on the same day of discharge. From first IPC discharge until mortality, 54.8% of patients were readmitted once, 23.9% were readmitted twice, 9.9% were readmitted 3 times, and 11.5% were readmitted 4 or more times. Being male, having a higher insurance premium level, having a longer length of stay during first IPC admission, being admitted to a teaching hospital, or being admitted to a tertiary hospital increased the adjusted hazard ratio for readmission.We found that terminal cancer patients in Taiwan received relatively late referrals for first admission to IPC and experienced a high rate of readmission after first discharge from IPC. Policies to improve hospice palliative care referrals and decrease readmissions should be considered.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1603
[Cu] Class update date: 160325
[Lr] Last revision date:160325
[Js] Journal subset:AIM; IM
[St] Status:In-Process
[do] DOI:10.1097/MD.0000000000002782

  2 / 2170453 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26796762
[Au] Autor:Flynn A; Dwight T; Harris J; Benn D; Zhou L; Hogg A; Catchpoole D; James P; Duncan EL; Trainer A; Gill AJ; Clifton-Bligh R; Hicks RJ; Tothill RW
[Ad] Address:The Peter MacCallum Cancer Centre (A.F., A.H., P.J., A.T., R.J.H., R.W.T.), East Melbourne, Victoria, 3002 Australia; The Department of Pathology (R.W.T., A.F.), University of Melbourne, Parkville, Victoria 3010, Australia; Cancer Genetics (T.D., D.B., R.C.-B.), Kolling Institute of Medical Research...
[Ti] Title:Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma.
[So] Source:J Clin Endocrinol Metab;101(3):1034-43, 2016 Mar.
[Is] ISSN:1945-7197
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are heritable neoplasms that can be classified into gene-expression subtypes corresponding to their underlying specific genetic drivers. OBJECTIVE: This study aimed to develop a diagnostic and research tool (Pheo-type) capable of classifying PPGL tumors into gene-expression subtypes that could be used to guide and interpret genetic testing, determine surveillance programs, and aid in elucidation of PPGL biology. DESIGN: A compendium of published microarray data representing 205 PPGL tumors was used for the selection of subtype-specific genes that were then translated to the Nanostring gene-expression platform. A support vector machine was trained on the microarray dataset and then tested on an independent Nanostring dataset representing 38 familial and sporadic cases of PPGL of known genotype (RET, NF1, TMEM127, MAX, HRAS, VHL, and SDHx). Different classifier models involving between three and six subtypes were compared for their discrimination potential. RESULTS: A gene set of 46 genes and six endogenous controls was selected representing six known PPGL subtypes; RTK1-3 (RET, NF1, TMEM127, and HRAS), MAX-like, VHL, and SDHx. Of 38 test cases, 34 (90%) were correctly predicted to six subtypes based on the known genotype to gene-expression subtype association. Removal of the RTK2 subtype from training, characterized by an admixture of tumor and normal adrenal cortex, improved the classification accuracy (35/38). Consolidation of RTK and pseudohypoxic PPGL subtypes to four- and then three-class architectures improved the classification accuracy for clinical application. CONCLUSIONS: The Pheo-type gene-expression assay is a reliable method for predicting PPGL genotype using routine diagnostic tumor samples.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1603
[Js] Journal subset:AIM; IM
[St] Status:In-Process
[do] DOI:10.1210/jc.2015-3889

  3 / 2170453 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26935518
[Au] Autor:Takahashi M; Aiba M; Sakurai T; Sakamoto N; Seok Yang K; Tsuda H; Shioji N; Isonuma H
[Ad] Address:Department of Geriatric General Medicene, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University Faculty of Medicine.
[Ti] Title:[A clinical analysis of elderly dementia patients with physical comorbidities].
[So] Source:Nihon Ronen Igakkai Zasshi;53(1):45-53, 2016.
[Is] ISSN:0300-9173
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:AIM: To investigate the current status of elderly dementia patients with physical illnesses and identify optimal care strategies for this growing population. METHODS: This retrospective study included elderly dementia patients who (i) received in-patient treatment for a physical comorbidity at the dementia ward of the Juntendo Tokyo Koto Geriatric Medical Center, and (ii) who were discharged from April 2009 to March 2011. RESULTS: The study population was 390 patients (144 males, 246 females), with a mean [±SD] age of 80.5 [±8.1] years. Two hundred thirteen of the patients had Alzheimer's disease; the remaining 177 had other types of dementia. The comorbidities necessitating admission were: malignant neoplasms (n=65), respiratory conditions (n=57), genitourinary conditions (n=50), trauma or fracture (n=41), and other (n=177). Among the 239 subjects who were hospitalized from their homes and who were discharged alive, 157 (65.7%) returned to their homes. The hospital stays of patients who were discharged were significantly shorter (P<0.000) and their N-ADL scores were significantly better at admission (P<0.013) and at discharge (P<0.000). The proportion of subjects who were capable of oral ingestion was significantly higher among the patients who were discharged to their homes (P<0.025). The subjects who lived in their homes alone at the time of hospitalization were significantly less likely to be discharged to their homes (P<0.018). CONCLUSIONS: Elderly dementia patients should ideally return home after hospitalization for comorbid illnesses. This was facilitated by minimizing their hospital stay. During in-patient treatment, efforts should be made to maintain their N-ADL levels and support their oral intake.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1603
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.3143/geriatrics.53.45

  4 / 2170453 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 26079778
[Au] Autor:Netzel BC; Grebe SK; Carranza Leon BG; Castro MR; Clark PM; Hoofnagle AN; Spencer CA; Turcu AF; Algeciras-Schimnich A
[Ad] Address:Department of Laboratory Medicine and Pathology (B.C.N., S.K.G.G., A.A.-S.), Division of Endocrinology, Metabolism, and Nutrition (S.K.G.G., B.G.C.L., M.R.C., A.F.T.), Mayo Clinic, Rochester, Minnesota 55905; Queen Elizabeth Hospital Birmingham (P.M.C.), Birmingham B15 2TH, United Kingdom; Departmen...
[Ti] Title:Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes.
[So] Source:J Clin Endocrinol Metab;100(8):E1074-83, 2015 Aug.
[Is] ISSN:1945-7197
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:CONTEXT: Measurement of thyroglobulin (Tg) by mass spectrometry (Tg-MS) is emerging as a tool for accurate Tg quantification in patients with anti-Tg autoantibodies (TgAbs). OBJECTIVE: The objective of the study was to perform analytical and clinical evaluations of two Tg-MS assays in comparison with immunometric Tg assays (Tg-IAs) and Tg RIAs (Tg-RIAs) in a cohort of thyroid cancer patients. METHODS: A total of 589 samples from 495 patients, 243 TgAb-/252 TgAb+, were tested by Beckman, Roche, Siemens-Immulite, and Thermo-Brahms Tg and TgAb assays, two Tg-RIAs, and two Tg-MS assays. RESULTS: The frequency of TgAb+ was 58%, 41%, 27%, and 39% for Roche, Beckman, Siemens-Immulite, and Thermo-Brahms, respectively. In TgAb- samples, clinical sensitivities and specificities of 100% and 74%-100%, respectively, were observed across all assays. In TgAb+ samples, all Tg-IAs demonstrated assay-dependent Tg underestimation, ranging from 41% to 86%. In TgAb+ samples, the use of a common cutoff (0.5 ng/mL) for the Tg-MS, three Tg-IAs, and the USC-RIA improved the sensitivity for the Tg-MSs and Tg-RIAs when compared with the Tg-IAs. In up to 20% of TgAb+ cases, Tg-IAs failed to detect Tg that was detectable by Tg-MS. In Tg-RIAs false-high biases were observed in TgAb+ samples containing low Tg concentrations. CONCLUSIONS: Tg-IAs remain the method of choice for Tg quantitation in TgAb- patients. In TgAb+ patients with undetectable Tg by immunometric assay, the Tg-MS will detect Tg in up to 20% additional cases. The Tg-RIA will detect Tg in approximately 35% cases, but a significant proportion of these will be clinical false-positive results. The undetectable Tg-MS seen in approximately 40% of TgAb+ cases in patients with disease need further evaluation.
[Mh] MeSH terms primary: Autoantibodies/analysis
Thyroglobulin/analysis
Thyroid Function Tests
Thyroid Neoplasms/diagnosis
[Mh] MeSH terms secundary: Adolescent
Adult
Aged
Aged, 80 and over
Autoantibodies/blood
Chromatography, Liquid
Cohort Studies
Female
Humans
Male
Middle Aged
Predictive Value of Tests
Prognosis
Radioimmunoassay/methods
Tandem Mass Spectrometry
Thyroglobulin/blood
Thyroid Function Tests/methods
Thyroid Function Tests/standards
Thyroid Neoplasms/blood
Young Adult
[Pt] Publication type:COMPARATIVE STUDY; EVALUATION STUDIES; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Name of substance:0 (Autoantibodies); 0 (anti-thyroglobulin); 9010-34-8 (Thyroglobulin)
[Em] Entry month:1511
[Cu] Class update date: 160703
[Lr] Last revision date:160703
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:150807
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2015-1967

  5 / 2170453 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27368054
[Au] Autor:Rundberg Nilsson A; Soneji S; Adolfsson S; Bryder D; Pronk CJ
[Ad] Address:Medical Faculty, Division of Molecular Hematology, Institution for Laboratory Medicine, Lund University, Lund, Sweden....
[Ti] Title:Human and Murine Hematopoietic Stem Cell Aging Is Associated with Functional Impairments and Intrinsic Megakaryocytic/Erythroid Bias.
[So] Source:PLoS One;11(7):e0158369, 2016.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Aging within the human hematopoietic system associates with various deficiencies and disease states, including anemia, myeloid neoplasms and reduced adaptive immune responses. Similar phenotypes are observed in mice and have been linked to alterations arising at the hematopoietic stem cell (HSC) level. Such an association is, however, less established in human hematopoiesis and prompted us here to detail characteristics of the most primitive human hematopoietic compartments throughout ontogeny. In addition, we also attempted to interrogate similarities between aging human and murine hematopoiesis. Coupled to the transition from human cord blood (CB) to young and aged bone marrow (BM), we observed a gradual increase in frequency of candidate HSCs. This was accompanied by functional impairments, including decreased lymphoid output and reduced proliferative potential. Downstream of human HSCs, we observed decreasing levels of common lymphoid progenitors (CLPs), and increasing frequencies of megakaryocyte/erythrocyte progenitors (MEPs) with age, which could be linked to changes in lineage-affiliated gene expression patterns in aged human HSCs. These findings were paralleled in mice. Therefore, our data support the notion that age-related changes also in human hematopoiesis involve the HSC pool, with a prominent skewing towards the megakaryocytic/erythroid lineages, and suggests conserved mechanisms underlying aging of the blood cell system.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1371/journal.pone.0158369

  6 / 2170453 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27367907
[Au] Autor:Bassani B; Bartolini D; Pagani A; Principi E; Zollo M; Noonan DM; Albini A; Bruno A
[Ad] Address:Scientific and Technological Pole, IRCCS MultiMedica, Milano, Italy....
[Ti] Title:Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/ß-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.
[So] Source:PLoS One;11(7):e0154111, 2016.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Medulloblastoma (MB), a neuroectodermal tumor arising in the cerebellum, represents the most frequent childhood brain malignancy. Current treatments for MB combine radiation and chemotherapy and are often associated with relevant side effects; novel therapeutic strategies are urgently needed. N-(4-Hydroxyphenyl) retinamide (4-HPR, fenretinide), a synthetic analogue of all-trans retinoic acid, has emerged as a promising and well-tolerated cancer chemopreventive and chemotherapeutic agent for various neoplasms, from breast cancer to neuroblastoma. Here we investigated the effects of 4-HPR on MB cell lines and identified the mechanism of action for a potential use in therapy of MB. Flow cytometry analysis was performed to evaluate 4-HPR induction of apoptosis and oxygen reactive species (ROS) production, as well as cell cycle effects. Functional analysis to determine 4-HPR ability to interfere with MB cell migration and invasion were performed. Western Blot analysis were used to investigate the crucial molecules involved in selected signaling pathways associated with apoptosis (caspase-9 and PARP-1), cell survival (ERK 1/2) and tumor progression (Wnt3a and ß-catenin). We show that 4-HPR induces caspase 9-dependent cell death in DAOY and ONS-76 cells, associated with increased ROS generation, suggesting that free radical intermediates might be directly involved. We observed 4-HPR induction of cell cycle arrest in G1/S phase, inactivated ß-catenin, and inhibition of MB cell migration and invasion. We also evaluated the ability of 4-HPR to target MB cancer-stem/cancer-initiating cells, using an MB spheroids model, followed by flow cytometry and quantitative real-time PCR. 4-HPR treatment reduced DAOY and ONS-76 spheroid formation, in term of number and size. Decreased expression of the surface markers CD133+ and ABCG2+ as well as Oct-4 and Sox-2 gene expression were observed on BTICs treated with 4-HPR further reducing BITIC invasive activities. Finally, we analyzed 4-HPR ability to inhibit MB tumor cell growth in vivo in nude mice. Taken together, our data suggest that 4-HPR targets both parental and MB tumor stem/initiating cell-like populations. Since 4-HPR exerts low toxicity, it could represent a valid compound in the treatment of human MB.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1371/journal.pone.0154111

  7 / 2170453 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27367976
[Au] Autor:Mustafa OM; Mohammed SF; Aljubran A; Saleh WN
[Ad] Address:aCollege of Medicine, Alfaisal University bDepartment of Pathology and Laboratory Medicine cDepartment of Medical Oncology, Oncology Center dDivision of Thoracic Surgery, Department of Surgery, King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh, Saudi Arabia.
[Ti] Title:Immature mediastinal teratoma with unusual histopathology: A case report of multi-lineage, somatic-type malignant transformation and a review of the literature.
[So] Source:Medicine (Baltimore);95(26):e3378, 2016 Jun.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Germ cell tumors (GCTs) represent a well-recognized group of heterogeneous neoplasms with diverse clinical, histopathological, diagnostic, and prognostic characteristics. We present a rare case of a locally aggressive, chemotherapy-resistant immature mediastinal teratoma with a peculiar histological finding of a multilineage somatic-type malignant degeneration. A 21-year-old male patient presented with a 3-week history of persistent, blood-tinged productive cough and shortness of breath. A contrast-enhanced computed tomography (CT) scan of the chest showed a heterogeneous mass occupying the right hemithorax and abutting on adjacent structures. CT-guided biopsy was consistent with immature teratoma. Combination chemotherapy with bleomycin, etoposide, and cisplatin was initiated, albeit without success; the mass showed interval progression in size, and surgical resection through clamshell incision was performed. Histological assessment of the resected mass confirmed the diagnosis of immature teratoma and revealed an extensive multilineage malignant differentiation into sarcomatous, carcinomatous, and melanomatous components. The patient underwent an uneventful recovery but presented 2 months later with extensive liver and bone melanomatous metastases. In this report, relevant findings from the literature are also highlighted. Despite being exceptionally rare, such tumors carry poor prognosis. Understanding the clinicopathological characteristics and biological behavior of such tumors may provide an insight into interventions tailored to improve the otherwise dismal disease outlook.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Js] Journal subset:AIM; IM
[St] Status:In-Data-Review
[do] DOI:10.1097/MD.0000000000003378

  8 / 2170453 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27033437
[Au] Autor:Hernández Boluda JC; Gómez M; Pérez A
[Ad] Address:Servicio de Hematología, Hospital Clínico Universitario, Valencia, España. Electronic address: hernandez_jca@gva.es.
[Ti] Title:Inhibidores de JAK2. [JAK2 inhibitors].
[So] Source:Med Clin (Barc);147(2):70-5, 2016 Jul 15.
[Is] ISSN:0025-7753
[Cp] Country of publication:Spain
[La] Language:spa
[Ab] Abstract:Pharmacological inhibition of the kinase activity of JAK proteins can interfere with the signaling of immunomodulatory cytokines and block the constitutive activation of the JAK-STAT pathway that characterizes certain malignancies, including chronic myeloproliferative neoplasms. JAK inhibitors may, therefore, be useful to treat malignancies as well as inflammatory or immune disorders. Currently, the most significant advances have been made in the treatment of myelofibrosis, where these drugs may lead to a remarkable improvement in the control of hyperproliferative manifestations. However, available data suggest that this treatment is not curative of myelofibrosis. In general, JAK2 inhibition induces cytopaenias, with this being considered a class side-effect. By contrast, the extrahaematologic toxicity profile varies significantly among the different JAK inhibitors. At present, there are several clinical trials evaluating the combination of ruxolitinib with other drugs, in order to improve its therapeutic activity as well as reducing haematologic toxicity.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Em] Entry month:1607
[Js] Journal subset:IM
[St] Status:In-Data-Review

  9 / 2170453 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27008850
[Au] Autor:Park JS; Kim HS; Bae YS; Cheong JH; Rha SY; Noh SH; Kim H
[Ad] Address:Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul Department of Internal Medicine, Yonsei University College of Medicine, Seoul....
[Ti] Title:Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer.
[So] Source:Jpn J Clin Oncol;46(6):507-16, 2016 Jun.
[Is] ISSN:1465-3621
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: The aim of this study is to find the frequency and the role of epidermal growth factor receptor expression as a prognostic biomarker in gastric cancer. METHODS: We evaluated the prognostic value and frequency of epidermal growth factor receptor expression and amplification using immunohistochemistry and silver in situ hybridization in a large cohort of curatively resected gastric cancer. RESULTS: Of the total of 935 cases, 294 (31.4%), 101 (10.8%) and 36 (3.9%) patients showed epidermal growth factor receptor 1+, 2+ and 3+ expression on immunohistochemistry, respectively. Epidermal growth factor receptor-positive (2+/3+) patients more frequently had intestinal type than epidermal growth factor receptor-negative (0/1+) patients (82.5 vs. 44.1%, P < 0.001). After adjusting for sex, age, stage and adjuvant chemotherapy, epidermal growth factor receptor-positive patients had a favorable overall survival outcome compared with epidermal growth factor receptor-negative patients (hazard ratio, 0.734; 95% confidence interval, 0.541-0.997; P = 0.047), especially in Stage III disease (hazard ratio, 0.676; 95% confidence interval, 0.472-0.968; P = 0.033). Among the 393 cases available for  in situ hybridization, the correlation between immunohistochemistry and in situ hybridization was statistically significant (P = 0.001). Thirteen patients with gene amplification (3.3%) did not show different survival outcome with others (P = 0.359). CONCLUSION: Epidermal growth factor receptor positivity was an independent favorable prognostic factor for gastric cancer, especially in Stage III disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1093/jjco/hyw030

  10 / 2170453 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 27367953
[Au] Autor:Martingano D; Gurm H; Oliff A; Martingano FX; Aglialoro G
[Ti] Title:Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm.
[So] Source:J Am Osteopath Assoc;116(7):480-4, 2016 Jul 1.
[Is] ISSN:1945-1997
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The fifth leading cause of cancer-related deaths among women in the United States is ovarian cancer. An estimated 21,980 new cases and 14,270 estimated deaths occurred nationwide in 2014. More than two-thirds of cases of ovarian cancer are diagnosed at stage III or IV when the peritoneal cavity or other organs are affected. Primary appendiceal malignant neoplasms may mimic advanced-stage ovarian cancer and can be misdiagnosed because of its presentation as a palpable adnexal mass. The authors describe a 42-year-old woman who was admitted to the department of obstetrics and gynecology to receive treatment for presumed advanced-stage ovarian cancer. She subsequently received a diagnosis of primary pseudomyxoma peritonei metastatic to the ovaries, mimicking a primary ovarian cancer by osteopathic structural examination findings, serum tumor markers, surgical exploration, and histopathologic confirmation.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1607
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.7556/jaoa.2016.092


page 1 of 217046 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information